Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumiyoshi Matsuura

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Organic Letters|July 14, 2006
Total synthesis and stereochemistry of pinnatoxins B and CFumiyoshi Matsuura, Junliang Hao, Reinhard Reents, et al.
Journal of the American Chemical Society|June 8, 2006
Unified total synthesis of pteriatoxins and their diastereomersFumiyoshi Matsuura, René Peters, Masahiro Anada, et al.
Journal of the American Chemical Society|June 15, 2006
Stereochemistry of pteriatoxins A, B, and CJunliang Hao, Fumiyoshi Matsuura, Yoshito Kishi, et al.
Thrombosis Research|July 6, 2013
Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleedingTadashi Nagakura, Kimiyo Tabata, Kazunobu Kira, et al.
Journal of Pharmacological Sciences|September 9, 2008
Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogsShunji Kasai, Takashi Inoue, Hideki Yoshitomi, et al.
European Journal of Pharmacology|September 16, 2006
E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitorNobuyuki Yasuda, Tadashi Nagakura, Takashi Inoue, et al.
Scientific Reports|June 19, 2019
A landmark in drug discovery based on complex natural product synthesisSatoshi Kawano, Ken Ito, Kenzo Yahata, et al.
Organic Letters|January 22, 2024
Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical TrialsYosuke Kaburagi, Kazunobu Kira, Kenzo Yahata, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Organic Letters|July 14, 2006
Total synthesis and stereochemistry of pinnatoxins B and CFumiyoshi Matsuura, Junliang Hao, Reinhard Reents, et al.
Journal of the American Chemical Society|June 8, 2006
Unified total synthesis of pteriatoxins and their diastereomersFumiyoshi Matsuura, René Peters, Masahiro Anada, et al.
Journal of the American Chemical Society|June 15, 2006
Stereochemistry of pteriatoxins A, B, and CJunliang Hao, Fumiyoshi Matsuura, Yoshito Kishi, et al.
Thrombosis Research|July 6, 2013
Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleedingTadashi Nagakura, Kimiyo Tabata, Kazunobu Kira, et al.
Journal of Pharmacological Sciences|September 9, 2008
Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogsShunji Kasai, Takashi Inoue, Hideki Yoshitomi, et al.
European Journal of Pharmacology|September 16, 2006
E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitorNobuyuki Yasuda, Tadashi Nagakura, Takashi Inoue, et al.
Scientific Reports|June 19, 2019
A landmark in drug discovery based on complex natural product synthesisSatoshi Kawano, Ken Ito, Kenzo Yahata, et al.
Organic Letters|January 22, 2024
Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical TrialsYosuke Kaburagi, Kazunobu Kira, Kenzo Yahata, et al.
Pageof 1